EpicentRx

Focus: EpicentRx is a publicly-traded biotechnology company focused on epigenetics and oncolytic virus therapies for rare and solid tumor indications. Founded in 2023 and headquartered in La Jolla, CA, the company is in early-stage clinical development with a pipeline concentrated on the lead candidate RRx-001.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About EpicentRx

AI assessmentNot Hiring

No open roles listed right now. Follow EpicentRx to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PSV

Cancer

N/A

Clinical Trials (1)

NCT03529539Expanded Access for PSV Personalized Oncolytic Viruses

N/A

Help build intelligence for EpicentRx

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge epigenetics and oncolytic virus platforms with multiple Phase 2/3 programs across solid tumors
Publicly-traded status provides liquidity and potential equity upside despite early revenue stage
Focused pipeline in oncology rare diseases offers opportunity to meaningfully impact underserved patient populations

Watch Out For

Company founded in 2023 with zero current clinical trials active—significant execution risk and unproven development capability
No revenue, no disclosed funding, no active job openings, and unknown employee count suggest early-stage instability and limited hiring momentum
Sparse pipeline visibility: RRx-001 lead program dispersed across 10+ indications with mixed Phase 1-3 status, indicating unfocused strategy or resource constraints

Generated by Claude from EpicentRx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RRx-001 + WBRT

Brain Metastases

PHASE_1

Clinical Trials (1)

NCT02215512Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases

Phase 1

RRx-001

Brain Tumor, Recurrent

PHASE_1

Clinical Trials (1)

NCT04525014RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

Phase 1

RRx-001

Malignant Solid Tumor

PHASE_1

Clinical Trials (1)

NCT02801097RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Phase 1

RRx-001 dose escalation with TMZ + RT

Glioblastoma

PHASE_1

Clinical Trials (1)

NCT02871843RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas

Phase 1

RRx-001

Malignant Solid Tumor

PHASE_1

Clinical Trials (1)

NCT02096341A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

Phase 1

RRx-001

Malignant Solid Tumor

PHASE_1

Clinical Trials (1)

NCT01359982Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

Phase 1

RRx-001

Malignant Solid Tumor

PHASE_1

Clinical Trials (1)

NCT02518958A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

Phase 1

AdAPT-001

Solid Tumor, Adult

PHASE_2

Clinical Trials (1)

NCT04673942A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Phase 2

RRx-001

Cholangiocarcinoma

PHASE_2

Clinical Trials (1)

NCT02452970RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Phase 2

RRx-001

Oral Mucositis

PHASE_2

Clinical Trials (1)

NCT03515538Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

Phase 2

RRx-001

Small Cell Carcinoma

PHASE_2

Clinical Trials (1)

NCT02489903RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2

RRx-001

Colorectal Neoplasms

PHASE_2

Clinical Trials (1)

NCT02096354A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Phase 2

RRx-001

Oral Mucositis

PHASE_2

Clinical Trials (1)

NCT05966194RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

Phase 2

RRx-001 + eLOOP Device

Carcinoma, Small Cell Lung

PHASE_3

Clinical Trials (1)

NCT05566041A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

Phase 3

RRx-001 + eLOOP Device

Carcinoma, Small Cell Lung

PHASE_3

Clinical Trials (1)

NCT03699956RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 16 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

14 pipeline

Marketed

Pipeline